Terns Pharmaceuticals Statistics
Total Valuation
TERN has a market cap or net worth of $549.60 million. The enterprise value is $324.56 million.
Important Dates
The last earnings date was Monday, August 5, 2024, before market open.
| Earnings Date | Aug 5, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
TERN has 70.37 million shares outstanding. The number of shares has increased by 24.73% in one year.
| Shares Outstanding | 70.37M |
| Shares Change (YoY) | +24.73% |
| Shares Change (QoQ) | +0.08% |
| Owned by Insiders (%) | 0.08% |
| Owned by Institutions (%) | 66.37% |
| Float | 45.52M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.51 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 21.02, with a Debt / Equity ratio of 0.00.
| Current Ratio | 21.02 |
| Quick Ratio | 20.57 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -38.92% and return on invested capital (ROIC) is -27.39%.
| Return on Equity (ROE) | -38.92% |
| Return on Assets (ROA) | -25.99% |
| Return on Capital (ROIC) | -27.39% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.45M |
| Employee Count | 66 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, TERN has paid $265,000 in taxes.
| Income Tax | 265,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +47.92% in the last 52 weeks. The beta is -0.38, so TERN's price volatility has been lower than the market average.
| Beta (5Y) | -0.38 |
| 52-Week Price Change | +47.92% |
| 50-Day Moving Average | 7.75 |
| 200-Day Moving Average | 6.57 |
| Relative Strength Index (RSI) | 53.22 |
| Average Volume (20 Days) | 953,403 |
Short Selling Information
The latest short interest is 1.80 million, so 2.56% of the outstanding shares have been sold short.
| Short Interest | 1.80M |
| Short Previous Month | 2.65M |
| Short % of Shares Out | 2.56% |
| Short % of Float | 3.96% |
| Short Ratio (days to cover) | 1.68 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -108.23M |
| Pretax Income | -95.63M |
| Net Income | -95.90M |
| EBITDA | -107.91M |
| EBIT | -108.23M |
| Earnings Per Share (EPS) | -$1.31 |
Full Income StatementBalance Sheet
The company has $225.30 million in cash and $249,000 in debt, giving a net cash position of $225.05 million or $3.20 per share.
| Cash & Cash Equivalents | 225.30M |
| Total Debt | 249,000 |
| Net Cash | 225.05M |
| Net Cash Per Share | $3.20 |
| Equity (Book Value) | 218.68M |
| Book Value Per Share | 3.11 |
| Working Capital | 219.28M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$78.99 million and capital expenditures -$94,000, giving a free cash flow of -$79.09 million.
| Operating Cash Flow | -78.99M |
| Capital Expenditures | -94,000 |
| Free Cash Flow | -79.09M |
| FCF Per Share | -$1.12 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |